Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Amgen to Make $2.7 Billion Investment in BeiGene; BeiGene to Develop 23 Amgen Candidates in China

publication date: Oct 31, 2019

BeiGene, a Beijing cancer biopharma, announced a blockbuster collaboration with Amgen that calls for Amgen to invest $2.7 billion into BeiGene while BeiGene agrees to develop and market 23 Amgen novel cancer candidates in China. One of the drugs is already approved in China and two others are approved outside of China. In addition, BeiGene will be in charge of China development for 20 Amgen pre-clinical molecules. All together, BeiGene will set aside $1.2 billion for development costs of the candidates. It said the agreement will build its China marketing business while its own drugs move into commercialization. The $2.7 billion Amgen investment represents a 20.5% stake in BeiGene, valuing the company at $13 billion. More details....

Stock Symbols: (NSDQ: BGNE; HK: 06160) (NSDQ: AMGN)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
August 25-27, 2020
China Standard Time
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China